Table 1.
Characterization of NG2+ cells in the aSVZ and RMS of the perinatal CNP-EGFP mouse
|
|
EGFP+ cells/μm3 |
Percentage of EGFP+ cells |
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NG2+/DC−
|
NG2+/DC+
|
NG2−/DC+
|
NG2−/DC−
|
NG2+/Er81+
|
NG2+/Nkx2.2+
|
Er81+/DC+
|
Nkx2.2+/Er81+
|
||||||||
| aSVZ | 3.1 ± 0.4 | 72.0 ± 2.6 | 10.1 ± 1.4 | 11.7 ± 2.1 | 16.7 ± 4.4 | 23.2 ± 1.9 | 42.2 ± 1.7 | 7.2 ± 2.3 | 3.7 ± 2.0 | |||||||
| RMS |
4.6 ± 0.7 |
28.7 ± 2.2 |
1.1 ± 0.4 |
25.7 ± 5.1 |
45.7 ± 6.2 |
18.0 ± 3.2 |
66.0 ± 4.4 |
26.3 ± 3.8 |
0 |
|||||||
The analysis of the SVZ and RMS was performed at different rostral levels (Fig. 3, green boxes) in the CNP-EGFP mouse at P8. An average of three to four sections from three different brains (9-12 sections total) were counted for the SVZ and RMS, respectively, to obtain an estimate of the total number of EGFP+ cells. Percentages of EGFP+ cells expressing NG2 proteoglycan, DC, Er81, and Nkx2.2 were estimated by scoring the number of cells double-labeled with the marker in question. Total EGFP+ cells counted ranged between 929 and 1108. Cell counting data in tissue sections are expressed as averages ± SEM.